Paraguay Medical Device Post-Market Compliance: Type I and Type II Post-Approval Changes (Articles 13-14)

1. Key takeaways

1. Article 13 divides post-approval changes into two categories:
   • Type I (Tipo I), immediate implementation: the change may be implemented immediately upon notification to DINAVISA;
   • Type II (Tipo II), deferred implementation: the change requires DINAVISA authorization before it may be implemented.
2. Article 14: the assessment period for Type II changes is 45 working days; corrections follow the 60 / 30 working day rule; where corrections are not filed on time or the technical assessment is unfavorable, the application to implement the change is denied.
3. Every change requires payment of the applicable fee, a sworn declaration submitted under Annex III, and the corresponding documentation required by Article 13.
4. Article 16: a change does not alter the expiry date of the sanitary registration or of the NSO; the expiry date remains the original one.

In day-to-day practice, most filings are Type I appearance and naming changes, while Type II concentrates in formulation, model and sales-condition decisions that typically originate in product management rather than regulatory affairs, which is why the classification step must sit inside the change control workflow itself.

2. Legal basis

The change regime is one of the most operationally dense parts of Resolution 226/2024. Article 13 supplies the classification and the notification or authorization track, Article 14 supplies the clock and the correction mechanics, Annex III supplies the sworn declaration template, and Article 16 closes the loop by protecting the integrity of the expiry date. The Instructivo repeats Articles 13 and 14 at filing level, so both the legal classification and the electronic submission workflow must be mastered by any team that manages a Paraguay portfolio through its life cycle.

The classification table is the operational heart of this regime: it lists, item by item, which modifications ride the notification track and which require prior authorization. Reading the table before planning any product or commercial change saves a full review cycle, because the difference between the two tracks is not procedural convenience but legality of implementation. A change that lands in the wrong category is not simply re-filed; it is exposed as an unreported change, with the suspension consequences described in article 45 of this series.

3. Expert insights

Insight one: the dividing line is whether the technical information or the substantive content changes. The change table assigns to Type I: appearance changes (labels, packaging, draft instructions for use); design changes that do not alter technical information; changes of the name of the registration holder, the manufacturer or the distributor; address changes; changes of distributor, commercialization entity or warehouse; changes of generic name, ECRI code and trade name; brand changes; and accessory changes that do not alter composition or function. Typical Type II entries include changes to the conditions of sale and model changes that affect composition, formulation or function. The classification is therefore not about the size of the modification in engineering terms, but about whether the approved technical content of the registration is touched.

Insight two: the Type II rule of authorization before implementation is a hard constraint. The legal effect of a Type I change is that notification itself enables implementation; for Type II, implementation is lawful only after authorization. Changing a label, introducing a modified model or shifting a sales channel before a Type II change is approved is treated as an unreported change and triggers the suspension consequences of Article 15. Project teams used to jurisdictions where implementation-with-notification is tolerated should recalibrate: in Paraguay the sequencing is not advisory, it is the boundary between a managed change and a compliance incident.

Insight three: because changes never extend validity, the schedule cannot be stretched through changes. Article 16 states expressly that a change does not modify the expiry date. Changes and renewal therefore run on two independent timelines, and frequent changes cannot be used to defer renewal preparation. The corollary for planning is positive: a well-run change ledger does not disturb the renewal countdown, so both processes can be staffed and budgeted separately without interference.

4. Practical recommendations

1. Establish a classification decision workflow for every change: determine Type I or Type II first, then prepare the documents. This avoids the costly scenario of filing as Type I and being required to convert to Type II after review has started.
2. Schedule Type II changes around the 45 working day assessment period plus a reserve for the correction window, and do not implement anything until authorization is granted.
3. Budget the fee for every change, since Article 13 applies it por cada modificación, that is, for each individual modification rather than per project or per product line.
4. Link the change ledger to the Annex IV declaration used at renewal, keeping ten years of traceability in one place so the renewal declaration can be assembled without archaeological work.

The fee point deserves its own line in project budgets because it scales linearly with portfolio activity: a company that files twenty Type I notifications a year pays the fee twenty times, and the Annex III sworn declaration effort is repeated for each. Estimating change-related cost per product family, rather than per company, gives a much truer picture of the running cost of a Paraguay registration.

A final observation on Article 16: because the expiry date is untouched by changes, the change ledger and the renewal countdown never interact. That independence is a feature. It allows regulatory affairs to process changes continuously without renegotiating the renewal plan, and it allows finance to forecast the renewal cost years ahead with confidence.

5. Verification checklist

• □ A classification decision has been completed for every change (Type I / Type II)
• □ Type II changes reserve the 45 working day assessment period in the schedule
• □ No physical implementation occurred before authorization of Type II changes
• □ The fee for each individual change is included in the budget
• □ The change ledger is linked to the Annex IV declaration

Regulatory information verified as of October 29, 2026.

GRZAN provides registration and post-market compliance support for medical device manufacturers, importers and authorized representatives in Paraguay. For assistance with change classification, submissions or any other regulatory matter, contact info@grzanglobal.com.